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Abstract 
Ineffective therapeutic treatments and inadequate repair ability in the central nervous system are disturbing prob‑
lems for several neurological diseases. Fortunately, the development of clinically applicable populations of stem cells 
has provided an avenue to overcome the failure of endogenous repair systems and substitute new cells into the dam‑
aged brain. However, there are still several existing obstacles to translating into clinical application. Here we review 
the stem‑cell based therapies for Parkinson’s disease and discuss the potential advantages and drawbacks. We hope 
this review may provide suggestions for viable strategies to overcome the current technical and biological issues 
associated with the application of stem cells in Parkinson’s disease.
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Background
Stem cells are undifferentiated cells that are able to dif-
ferentiate into multiple specialized cell types. Since 
stem cells have the potential to replace or restore lost 
cells, they have been evaluated and considered as poten-
tial therapeutic agents in neuronal diseases. Numer-
ous studies have focused on stem cell therapy in spinal 
cord injury, spinal muscular atrophy, brain ischemia, 
amyotrophic lateral sclerosis and other neurodegenera-
tive diseases (Nicaise et  al. 2015; Mendonca et  al. 2015; 
Lukovic et  al. 2015; Frattini et  al. 2015; Ju et  al. 2014). 
Because neurodegenerative diseases are often associated 
with regional cell loss, cell transplantation therapies may 
effectively restore and replace cells in the damaged tis-
sues. Therefore, we will highlight several milestones in 
the development of stem cell therapy for Parkinson’s dis-
ease (PD), which is the second most common neurode-
generative diseases.
Characteristics of various stem cells for therapy
There are several types of stem cells under consideration 
for therapeutic purposes. Below we will introduce four 
kinds of stem cells, including embryonic stem cells (ES 
cells), induced pluripotent stem cells (iPSCs), neural stem 
cells (NSCs) and mesenchymal stem cells (MSCs).
Embryonic stem cells (ES cells)
ES cells are pluripotent cells derived from the inner cell 
mass (ICM) of blastocysts. These cells are able to dif-
ferentiate into three germ layers, and subsequently may 
be driven to develop into many different types of cells 
(Thomson et  al. 1998). In neuronal systems, prior stud-
ies have showed that functional neurons, astrocytes, and 
oligodendrocytes could be derived from ES cells in vitro 
(Wichterle et al. 2002; Zhang et al. 2001). As a result, ES 
cells transplant has been widely suggested in several neu-
rodegenerative diseases or brain injuries (Aleynik et  al. 
2014). However, their high capacity of self-renewing and 
pluripotency lead to high risk of tumor formation, espe-
cially teratoma (Gordeeva 2011). Another major limita-
tion is the ethical issue regarding their origin. Isolating 
ICM from blastocysts destroys early embryos and raises 
the moral concern (Daar and Sheremeta 2003). Due 
to the high tumorigenicity and ethical considerations, 
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non-ES cells have become a major focus of cell-based 
therapies, such as adult stem cells.
Induced pluripotent stem cells (iPSCs)
In 2006, Kazutoshi Takahashi and Shinya Yamanaka 
established the induced pluripotent stem cells, which 
are ES-like cells transformed from fibroblasts (Taka-
hashi and Yamanaka 2006). This method is accomplished 
by introducing four transcription factor genes encoding 
Oct4, Sox2, Klf4, and c-Myc into skin fibroblasts. Since 
iPSCs may be derived directly from adult tissues, the 
risk of immune rejection and complicated ethical issues 
are avoided when used as a substrate for transplanta-
tion. Therefore, iPSCs were recently used as a potential 
cell source to repair neuronal networks in various CNS 
diseases, such as ischemic stroke and PD (Wernig et  al. 
2008; Yuan et al. 2013).
However, one major drawback of the iPSC technology 
is that c-Myc is well-defined as an oncogene, and reacti-
vation of c-Myc increases the risk of tumor formation 
(Kawai et  al. 2010). Yamanaka et  al. modified the repro-
gramming protocol by using only Oct4, Sox2 and Klf4 
without c-Myc, and it significantly decreased the tumo-
rigenicity; however, this modified method significantly 
reduced the efficiency of iPSC formation (Nakagawa 
et al. 2008). Furthermore, Oct4, Sox2 and Klf4 are over-
expressed or activated in various types of cancer as well 
(Peng et al. 2010; Raguel et al. 2009; Sholl et al. 2010), sug-
gesting high risk of tumorigenicity as using these cells for 
transplantation. Recently, Chiou et al. (2013) reported that 
poly (ADP-ribose) polymerase 1 (Parp1) could be used for 
iPSC production, and it significantly decreases the risk 
of tumorigenicity, implying the major drawback could be 
overcome. However, the risk of teratoma formation after 
iPSCs transplantation could not be completely eliminated 
(Petit et al. 2014). Despite the obvious potential of iPSCs 
for cell-based therapy, this major hurdle should still be 
overcome before clinical use can be attempted.
Neural stem cells (NSCs)
NSCs are stem-like progenitor cells that are isolated 
from either fetal brains or specific regions in adult brains 
(Kelly et  al. 2004; Kukekov et  al. 1999). In adult tissue, 
the subgranular zone (SGZ) in the dentate gyrus of the 
hippocampus and the subventricular zone (SVZ) of the 
lateral ventricles are two restricted regions produc-
ing NSCs, and these two regions confer neurogenesis in 
adult brain (Ming and Song 2011). NSCs are multipotent 
stem cells and recapitulate the developmental restric-
tion toward a neural lineage. Therefore, these cells could 
be differentiated into neurons, astrocytes and oligoden-
drocytes (Jiang et  al. 2012). Due to this specific lineage 
restriction, the risk of tumor formation is reduced, and 
NSCs are more easily guided toward neuronal differen-
tiation. However, these cells cannot be isolated in large 
numbers, and it is also challenging to maintain or expand 
the cells in  vitro over long periods of time (Anderson 
et al. 2007). As a result, the application of NSCs for trans-
plantation is still limited.
Mesenchymal stem cells (MSCs)
Mesenchymal stem cells are non-hematopoietic and 
multipotent cells first retrieved from the stromal area 
of the adult bone marrow (Fridenshtein 1991). In addi-
tion to bone marrow, MSCs may also be derived from a 
variety of non-marrow tissues, including placenta, mus-
cle, skin, dental pulp, adipose tissue, umbilical cord and 
amniotic fluid (Jiang et  al. 2012; Minguell et  al. 2001). 
Since they can be retrieved from adult tissues, ethical 
concerns for MSCs could be avoided. Furthermore, one 
unique property of MSCs is immunomodulation, which 
may allow the cells to escape the surveillance of the 
host’s immune system or reduce the immune response of 
hosts (Guo et al. 2014; Glenn and Whartenby 2014). This 
characteristic would be an important concern for use in 
transplantation.
Bone marrow MSCs (BMSCs)
Bone marrow is the most common tissue from which 
MSCs are derived. The advantage of BMSCs is that these 
cells are relatively easy to be collected from patients’ own 
bone marrow without further CNS damage. Therefore, 
BMSCs may provide a relatively safe, ethical and immuno-
logically favorable source for transplantation. In addition, 
application of BMSCs for the treatment of hematopoietic 
diseases began decades ago, which suggests that the pro-
tocol of isolation has been well established. As a result, 
BMSCs are considered as a resource with easier access. 
Another important feature is that BMSCs are able to cross 
the blood brain barrier and migrate throughout the brain 
(Li et al. 2001). This important advantage suggests the pos-
sibility that reconstruction/replacement of damaged brain 
tissues may be initiated via peripheral delivery without 
invasive methods. Furthermore, several reports have shown 
that BMSCs could be differentiated into neuronal cells 
(Zhao et al. 2015; Haragopal et al. 2015). These results sup-
port the therapeutic potential of BMSCs for neurological 
disease. However, the efficiency of differentiation into neu-
ronal cells is low, and these cells may only be maintained 
for a few passages (Long et al. 2005). These drawbacks limit 
the potential application of BMSCs for transplantation.
Umbilical cord blood (UCB) cells
UCB is collected from the umbilical cord attached to the 
placenta during birth. UCB is comprised of hematopoi-
etic stem cells, endothelial cell precursors, mesenchymal 
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progenitors and multipotent/pluripotent lineage stem 
cells (Berger et  al. 2006; Erices et  al. 2000). Since these 
materials are considered to be waste products, UCB 
cells may be easily procured without damage to donors, 
thereby circumventing ethical issues. Another important 
characteristic of UCB cells is that they are more juve-
nile than those collected from adult tissues; therefore, 
these cells are easier to expand in culture, more tolerant 
to human leukocyte antigen (HLA) disparities, and sig-
nificantly lower risk for immune rejection (Danby and 
Rocha 2014). The neurological pluripotency of UCB cells 
has been studied in several reports. Jang et  al. showed 
that cord-derived hematopoietic stem cells could be dif-
ferentiated into neuronal and glial cells (astrocytes and 
oligodendrocytes) using retinoic acid (Jang et  al. 2004). 
Similarly, non-hematopoietic stem cells in UCB (most 
likely mesenchymal progenitors) also process the capabil-
ity to differentiate into neural-like cells in vitro (Buzanska 
et  al. 2006). Although the pluripotency of UCB toward 
neuronal lineage is beneficial for transplantation, the lim-
ited amount of cells which could be collected remains the 
main drawback for the utilization of UCB. Because of the 
restricted volume of cells collected from cord blood, the 
amount of stem cells in UCB is 10-fold less than that of 
bone marrow. As a result, UCB cells only are applicable 
in children or young adults (Moise 2005). Several strate-
gies have been proposed to overcome this problem. For 
example, transplantations with double unit cord blood 
and ex vivo expansion of UCB cells have proved to offer 
better outcomes (Brunstein et  al. 2009; Yoshimi et  al. 
2008). Therefore, UCB cells are still considered as one of 
potential resources for transplantation.
Application of stem cells in Parkinson’s disease
Parkinson’s disease
Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder, affecting 1 % of the popula-
tion worldwide after the age of 65. The typical symptoms 
of PD are bradykinesia, rigidity, and resting tremor (Tan-
ner and Goldman 1996). The main pathological features 
are extensive loss of dopamine (DA) neurons in the Sub-
stantia Nigra pars compacta and the accumulations of 
cytoplasmic eosinophilic inclusions, Lewy bodies (LB) 
(Forno 1996). The cause of degenerated nigrostriatal 
dopaminergic neurons remains largely unknown. Cur-
rent therapeutic choices for PD patients include levo-
dopa, DA agonists, monoamine oxidase inhibitors, and 
deep brain stimulation (DBS). Generally, the effectiveness 
of oral medications begins to wear-off after 5 years (Jank-
ovic 2005). Moreover, these treatments cannot repair the 
damaged DAstriatal projections; therefore, restorative 
approaches should be considered in order to improve 
the therapeutic effect. Since PD patients display selective 
degeneration of SN DA neurons, cell replacement thera-
pies which can produce functional DA neurons may be a 
valuable therapeutic approach.
To achieve a successful cell-based therapy in PD, some 
criteria for cell transplantation are generally suggested 
(Lindvall and Hagell 2000; Lindvall and Kokaia 2006; 
Lindvall et  al. 2004). (1) The cells should possess the 
molecular, morphological and electrophysiological prop-
erties of DA neurons in substantia nigra; (2) the grafts 
should be able to reverse the motor deficits of PD; (3) the 
therapy should enable 100,000 or more DA neurons to 
survive long term in human putamen; (4) the grafted cells 
should re-establish a dense terminal network throughout 
the striatum to functionally integrate into host neural cir-
cuitries. Here we review the progress of stem cell thera-
pies and discuss the major problems encountered in PD.
Graft
The content of graft is the critical issue when perform-
ing the transplantation. It is currently unknown whether 
symptomatic relief would be best achieved by implanting 
a pure population of DA neurons or a graft containing 
a portion of glial cells. Several studies support the nec-
essary role of astrocytes for neural differentiation dur-
ing embryonic development, implying that glial cells are 
important for fate determination of precursors during 
implantation (Song et al. 2002). Therefore, mesencephalic 
tissues containing glial cells were most often used in pre-
vious studies. Another key issue in performing grafts for 
PD treatment is that implanting the most suitable sub-
type of DA neurons is also critical for the outcome of 
transplantation. DA rich-ventral mesencephalic grafts 
contain two types of DA neuron progenitors, including 
A9 Substantia Nigra neurons and A10 dopamine neurons 
of the Ventral Tegmental Area (Thompson et  al. 2005). 
Only the A9 subtype DA neurons send innervated axons 
into the striatum in rats (O’Keeffe et  al. 2008; Grealish 
et  al. 2010), suggesting that mesencephalic grafts with 
more A9 subtype DA neurons would be more beneficial 
for PD treatment.
In late 1980s, clinicians transplanted human embryonic 
or fetal ventral mesencephalic tissues into PD patients, 
but the results were varied. In Madrazo and Lindvall’s 
open-label trials, PD patients showed improvement of 
Unified Parkinson’s Disease Rating Scale (UPDRS) after 
receiving fetal DA neuron graft (Madrazo et  al. 1988; 
Lindvall et  al. 1989). However, the results from two 
double-blind trials funded by the National Institutes of 
Health (NIH) in the 1990s showed no significant effects 
(Freed et al. 2001; Olanow et al. 2003). Even more, sev-
eral side-effects have been shown in PD patients who 
received these transplantations. The results of these two 
open-label and double-blind trials raise critical issues 
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regarding ethical considerations, and may enhance con-
troversy which can dissuade the potential use of trans-
plants for PD.
In the following, we will review different alternative 
sources for the transplantation in PD.
ES cell‑derived DA neurons
ES cells are one important source that has been used to dif-
ferentiate into DA neurons in the laboratory. Rodent and 
human ES cell-derived DA neurons have been shown to 
survive and function after transplantation into the striatum 
of PD rats (Kim et al. 2002; Yang et al. 2008). In 2005, Tak-
agi et al. reported that primate ES cell-derived DA neurons 
survived in the putamen of 1-methyl-4-phenyl-1, 2, 3, 6-tet-
rahydropyridine (MPTP)-lesioned monkeys. Furthermore, 
the uptake of [18F]-DOPA also increased 14  weeks after 
transplantation, suggesting exogenous ES cell-derived DA 
neurons could offer the functional recovery of DA neurons. 
Until now, ES cells are still the most promising source to 
differentiate into DA neurons (Kim et al. 2002; Rodriguez-
Gomez et al. 2007); however, the efficiency to differentiate 
into DA neurons and the survival rate of these neurons 
after transplantation are still low. For example, prior reports 
showed less than 300 tyrosine hydroxylase (TH)-positive 
neurons survived after transplanting 100,000–400,000 ES 
cells into the striatum (Brederlau et al. 2006; Ben-Hur et al. 
2004). Therefore a critical issue that must be resolved to 
enhance recovery after transplantation in PD is improve-
ment of the differentiation and survival rate.
iPSC‑derived DA neurons
Since the iPSC technique was established in 2006 (Taka-
hashi and Yamanaka 2006), another cell source to gen-
erate DA neurons was provided. In 2008, DA neurons 
were first generated from mouse iPSCs and transplanted 
into the striatum of a rat PD model, thereby alleviating 
the symptoms of PD (Wernig et  al. 2008). In 2010, DA 
neurons differentiated from iPSCs of PD patients were 
transplanted into PD transgenic rats, and these neurons 
survived for several months and further alleviated the 
symptoms of PD (Hargus et al. 2010). Most importantly, 
these transplanted cells did not display α-synuclein posi-
tive inclusion bodies in hosts, suggesting that performing 
autografts in PD patients may be a viable option. How-
ever, several reports have mentioned patient-derived 
iPSCs are still more vulnerable to PD because of muta-
tions or epigenetic markers in cells (Badger et  al. 2014; 
Beevers et al. 2013; Sanchez-Danes et al. 2012). Further-
more, the risk of tumor formation still needs to be mini-
mized before clinical application can be realized (Petit 
et al. 2014). Since the technique of iPSC production was 
only developed a few years ago, further optimization may 
overcome these drawbacks.
NSCs and NSC‑derived DA neurons
NSCs are multipotent stem cells that are defined as “neu-
rally” destined cells and retain their regional specificity 
(Horiguchi et  al. 2004). Therefore, NSCs that are derived 
from a primarily DA location, such as ventral mesencepha-
lon (VM), should be the most appropriate source of DA 
neurons. Several reports have shown the potential ability 
of NSCs to differentiate into DA neurons (Tan et  al. 2014, 
2015), and also demonstrated the improvement of symp-
toms in PD models after transplantation of NSC-derived 
DA neurons (Parish et al. 2008; Redmond et al. 2007). Addi-
tionally, overexpression of different genes, such as Lmx1a, 
glial cell line-derived neurotrophic factor (GDNF), Brn4 
and TH, in NSCs has enhanced the beneficial effects of 
NSC-derived DA neurons (Tan et al. 2014; Wu et al. 2015; 
Wakeman et al. 2014). In animal studies, NSC-derived DA 
neurons overexpressing Nurr1, a critical factor involved in 
DA specification and survival, has led to functional improve-
ment in rats treated with 6-hydroxydopamine (6-OHDA), a 
toxic-induced PD model (Park et al. 2006). However, the sur-
vival rate of TH positive neurons after transplantation was 
less than 4.3 % (Park et al. 2006; Studer et al. 1998). In 2008, 
Parish et al. transfected Wnt5a into NSCs from mouse VM, 
generating tenfold more DA neurons with TH positive sig-
nal than the conventional FGF2-treated NSCs from VM and 
causing functional recovery in 6-OHDA mice (Parish et al. 
2008). Aside from VM, researchers have also derived NSCs 
from the SVZ, which is another well-known source for these 
cells. The transplantation of NSCs from SVZ enhanced the 
recovery of PD symptoms, but the survival rate of these cells 
was still low (Meissner et al. 2005; Richardson et al. 2005). 
Therefore, the most important issue that must be overcome 
in order to achieve NSC transplantation is to increase the cell 
number and survival rate of transplanted cells.
MSCs
Unlike studies using other stem cells, MSCs were grafted 
into PD models without differentiation in  vitro in most 
studies; however, the spontaneous differentiation abil-
ity of BMSCs after transplantation is low (Mezey et  al. 
2000). Li et  al. bilaterally injected BMSCs into striatum 
of MPTP-lesioned mice, and these cells showed TH 
immunoreactivity and promoted motor recovery (Li et al. 
2001). However, only 0.8 % of implanted cells expressed 
TH immunoreactivity. To address the low differentiation 
rate, delivery of Notch1 intracellular domain (NICD), 
basic fibroblast growth factor (bFGF), forskolin, ciliary 
neurotrophic factor (CNTF) and GDNF has been used 
to efficiently induce BMSC differentiation into neu-
ronal cells and increase the proportion of TH-positive 
cells (Dezawa et al. 2004). Moreover, the transplantation 
of these treated cells into 6-OHDA rats prevented DA 
neurons from degeneration (Glavaski-Joksimovic et  al. 
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2009). Most importantly, in a clinical trial using BMSCs 
treated with bFGF, workers transplanted cells unilaterally 
into the ventricular zone of advanced PD patients, who 
showed modest clinical improvement at 12  months and 
no tumor formation (Venkataramana et  al. 2010). This 
result suggests that BMSCs may be a good choice con-
cerning the issue of safety.
MSCs isolated from umbilical cords have also shown 
beneficial effects in 6-OHDA PD models (Mathieu et  al. 
2012; Weiss et  al. 2006). However, the low differentia-
tion potential of UCB cells is similar to that of BMSCs. To 
improve the differentiation rate, UCB cells were cultured 
with sonic hedgehog and fibroblast growth factor-8 (FGF-
8). Cells treated in this manner could reach 12.7 % neuronal 
differentiation, and these cells successfully ameliorated 
apomorphine-induced rotations in 6-OHDA lesioned rats 
(Fu et al. 2006). Overall, transplantation of undifferentiated 
MSCs or differentiated UCBs could all improve the symp-
toms of PD. Since there is no report to compare the differ-
ence between these cells, further studies will be necessary 
to conclude which source would be preferable.
In summary, iPSCs, NSCs, and MSCs are the most 
likely sources of stem cells for PD therapy. In all cases, 
autografts may be used as demonstrated by several suc-
cesses in rodent and primate PD models. However, the 
diverse differentiation methods, low production rate, and 
low survival rate after transplantation are still obstacles 
that need to be overcome before clinical use.
Patient selection
The status of PD patients is a critical factor affecting 
the outcome after transplantation. Though prior clini-
cal studies have reported diverse effects of transplanta-
tion in PD patients (Madrazo et  al. 1988; Lindvall et  al. 
1989; Freed et  al. 2001; Olanow et  al. 2003), there are 
some conclusions that may be drawn from detailed anal-
ysis. Piccini et al. implanted embryonic ventral mesence-
phalic tissues into putamen or caudate of nine patients, 
and [18F]-DOPA PET was performed preoperatively and 
1 or 2 years post-operatively. According to their results, 
patients without dopaminergic denervation outside the 
grafted striatal areas showed the best functional outcome 
after transplantation (Piccini et  al. 2005). In Olanow’s 
trial, less severe patients (UPDRS <50 points during “off” 
medication) responded significantly better to fetal grafts 
(Olanow et al. 2003). Freed and coworkers suggested that 
patients with younger age or better levodopa response 
before surgery might benefit more from cell transplanta-
tion (Freed et al. 2001). Ma et al. used [18F]-DOPA PET 
to evaluate the outcome of 33 participants 2–4  years 
after transplantation and also found that younger recipi-
ents had better clinical improvement (Ma et  al. 2010). 
In summary, individuals who are young and have better 
preoperative levodopa responsiveness will be more suita-
ble for cell transplantation. In addition, patients with DA 
neurons loss restricted to the caudate-putamen will also 
receive more symptomatic benefit after transplantation.
Immune response
Although the brain is regarded as an immune-privileged 
site, the host immune system still responds to the grafts. 
The interaction between implantation and the endogenous 
immune system affects the survival of grafted cells. In sev-
eral clinical trials, transplantation without adequate immu-
nosuppression may have led to poor outcomes (Freed et al. 
2001; Olanow et  al. 2003), while transplantation with an 
immunosuppressant, such as cyclosporine, azathioprine 
and prednisolone, produced better effects (Lindvall et  al. 
1989). Unfortunately, patient symptoms deteriorated after 
withdrawal of immunosuppression, and autopsy showed 
grafts were surrounded by activated microglia and immune 
reactivity (Olanow et  al. 2003). These results imply that 
immune reactions exert a negative effect during transplan-
tation, and it would be necessary to use an immunosup-
pressant in combination with grafting; however, further 
studies are still needed to determine the optimal immuno-
suppressant and the duration of treatment.
Major issues after grafts
According to the reports of several cell-based studies in 
both animals and humans, there are two major concerns 
related to grafts.
Graft Induced Dyskinesia (GID)
The occurrence of dyskinesia after transplantation was 
first reported by Defer et  al. (1996), but did not receive 
much attention until Freed’s trial in 2001 (Freed et  al. 
2001). They described the development of “graft induced 
dyskinesia (GID)” in 15 % of transplanted patients 1 year 
after transplantation. This unexpected symptom reached 
56 % in Olanow’s study (Olanow et al. 2003). It is specu-
lated that the number of grafted cells used in the surgery-
controlled clinical trials was less than those of other more 
successful studies (Lindvall et al. 1989; Freed et al. 2001). 
Additionally, immunosuppression may be also an impor-
tant factor since dyskinesia did not develop until immu-
nosuppression withdrawal in several reports (Olanow 
et al. 2003; Piccini et al. 2005; Lane et al. 2008). The other 
possible issue is that heterogeneous grafts were found 
in ventral putamen, containing serotonergic neurons. 
These grafts led to islands of reinnervation and abnormal 
production of DA (Ma et al. 2002; Carlsson et al. 2009). 
Therefore, transplanting sufficient number of cells con-
taining a pure population of DA neurons in basal gan-
glion with immunosuppression is suggested to avoid the 
development of GID.
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Grafts affected by PD process
Evidence that PD pathology may propagate from host 
to grafts is emerging (Kordower et al. 2008a, b; Li et al. 
2008). The presence of LBs and Lewy neurites in grafted 
DA neurons were generally observed 11–16  years after 
human fetal mesencephalic transplantation (Kordower 
et al. 2008a, b; Li et al. 2008; however,α-synuclein stain-
ing is generally not detectable in adults younger than 
20  year-old (Chu and Kordower 2010). These observa-
tions imply that PD pathology can be transferred from 
host to graft (Visanji et  al. 2013). The exact reasons for 
this negative outcome remain unresolved. A recent 
report showed that fetal cell transplantation in two PD 
patients remains highly functional even 15–18 years after 
surgery (Kefalopoulou et  al. 2014). Therefore, although 
the spread of PD pathology may occur after transplanta-
tion, the period of beneficial effects from transplantation 
is still longer than that of current medications, suggesting 
stem cells still could be a potential clinical therapy.
Mechanisms of stem cell therapy in PD
From the positive results of prior studies, the effects of 
stem cell therapy on PD can be classified into two catego-
ries. The first is a direct repair pathway, which includes 
augmenting endogenous neurogenesis, DA neuron 
differentiation (Park et  al. 2012), DA release (Rodri-
guez-Gomez et  al. 2007; Bouchez et  al. 2008), striatum 
reinnervation (Kordower et al. 1995) and neural circuits 
integration (Piccini et al. 2000; Bjorklund et al. 2002). The 
second is indirect repair system through trophic factors. 
Stem cells express various neurotrophic factors, such as 
brain derived neurotrophic factor (BDNF), nerve growth 
factor (NGF), cerebral dopamine neurotrophic factor 
(CDNF) or glial-derived neurotrophic factor (GDNF), 
and facilitate DA neuronal differentiation and mainte-
nance. These bystander effects are especially likely to 
result from grafts comprised of NSCs and MSCs (Rafuse 
et al. 2005; Tolar et al. 2010; Yasuhara et al. 2006; Lu et al. 
2003). However, it is still hard to distinguish clearly which 
pathway plays a dominant role, and, as a result, it is gen-
erally assumed that both direct and indirect pathways 
contribute to the beneficial effects after transplantation.
Conclusion
There is still no cure for PD since the precise mechanisms 
of this disease are largely unknown. High expectations 
have been placed on stem cell therapy to achieve this goal 
since many of the cell-based studies on PD animal mod-
els have shown positive results; however, the outcomes 
in clinical trials have not been consistent or convincing. 
This is possibly due to a combination of factors, such as 
patient selection, amount and mode of tissue engraft-
ment and the level of immunosuppression. Additionally, 
another side effect to be considered is GID. Fortunately, 
grafted tissues were not affected by PD progression 
within 10  years after transplantation, so the treatment 
of PD with stem cell grafts is still a promising direction. 
The major advantage of this strategy is the restorative 
and trophic abilities of the grafted cells which reach far 
beyond drugs prescribed in current practice.
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